Bxxxxx its sublicensee or their respective Affiliates shall have the right to determine the names and trademarks to use in connection with the promotion, marketing and sale of Products, and shall own and maintain such trademarks for use in connection with the promotion, marketing and sale of Products; provided, however, that Bxxxxx shall include on all packaging, labeling and marketing and promotional materials regarding any Product the name Halozyme, and the mxxx Enhanze (or such other mxxx reasonably requested by Halozyme) as a secondary mxxx, reasonably identifying that such product incorporates technology of Halozyme. Nothing in this Agreement shall create an obligation on Halozyme to register or otherwise maintain in force any marks.
Bxxxxx. XXXXXX ONCOLOGY and THRESHOLD undertake to each other to keep, and shall procure that their respective Affiliates, Sub-Licensees, employees, directors, officers, consultants and contractors (including those of any Affiliate) shall keep, confidential all information marked “confidential” received from each other during or in anticipation of – but after the effective date of the confidentiality agreement between the parties dated October 4, 2002 – this Agreement however obtained and in whatever form (the “Confidential Information”) provided that Confidential Information shall not include the following:
Bxxxxx. Xxxler agrees to the following undertakings in its capacity as a Broker-Dealer with regard to its Registered Representatives for Contracts:
Bxxxxx shall engage Halozyme, and Halozyme shall have the exclusive right, to conduct development and regulatory work for the PH20 Drug component of each Product. All such activities by Halozyme shall be conducted at the reasonable request of Bxxxxx pursuant to a mutually acceptable written workplan that is customary in the industry. Following the end of each calendar quarter, Halozyme shall invoice Bxxxxx for the fully burdened cost to Halozyme to conduct such activities, and Bxxxxx shall pay each such invoice within sixty (60) days after receipt.
Bxxxxx. AMERICAN REBEL HOLDINGS, INC., /s/ SXXXXX XXXXXX a Nevada corporation SXXXXX XXXXXX BY: /s/ Cxxxxxx Xxxxxx Xxxx Xx DATED: 4/10/2024 NAME: Cxxxxxx Xxxxxx Xxxx Xx TITLE: CEO DATED: 4/9/2024
Bxxxxx. (but not its Affiliates) shall be permitted, pursuant to the Licenses granted to Bxxxxx in Section 4.1(a) of this Agreement, to grant Sublicenses to Permitted Sublicensees; provided, however, that any such sublicensing by Bxxxxx is in compliance with the requirements and restrictions of this Section 4.3. Any Sublicense granted by Bxxxxx that is not in compliance with the requirements and restrictions of this Section 4.3 shall be null and void.
Bxxxxx. ONCOLOGY will conduct animal studies to determine dose titration of the combination of Glufosfamide and gemcitabine and one xenograft study with human pancreatic cancer tissue using this combination with changing treatment sequences (Glufosfamide and gemcitabine simultaneously, Glufosfamide then gemcitabine, or gemcitabine first). BAXTER may conduct additional animal studies with other xenograft types as well as a combination study of Glufosfamide with 5-FU. BAXTER will complete such studies and report the results therefrom to THRESHOLD no later than 15 November 2003. During the conduct of the foregoing studies, BAXTER shall keep THRESHOLD informed of the status of such studies and the results thereof on an ongoing basis.
Bxxxxx supplying to Oravax all Technical Information which is relevant and desirable and which will enable Oravax to carry out Process Development and Manufacture; and
Bxxxxx hereby authorises Oravax to use Bxxxxx’x intellectual property (excluding trade marks) on or in relation to the Products for the purpose only of exercising its rights and performing its obligations under this Agreement.
Bxxxxx and Oravax hereby acknowledge that neither of them shall acquire any rights in respect of the others intellectual property in relation to the Products or the Manufacture thereof or of the goodwill associated therewith.
